Company Overview of Polaris Pharmaceuticals, Inc.
Polaris Pharmaceuticals, Inc. engages in research and development of protein drugs to treat cancer. The company was founded in 2006 and is based in San Diego, California.
9373 Towne Centre Drive
San Diego, CA 92121
Founded in 2006
Key Executives for Polaris Pharmaceuticals, Inc.
Chief Executive Officer and President
Co-Founder and Vice President of Medical Affairs
Executive Vice-President of Regulatory Affairs
Compensation as of Fiscal Year 2016.
Polaris Pharmaceuticals, Inc. Key Developments
Polaris Group Reports Phase III Study Results of ADI-PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma
Jun 6 16
Polaris Group announced that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI-PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]). However, analysis of study data revealed that patients with arginine depletion for 7 weeks or longer had a median OS of 12.5 months, compared to 6.3 months (P < 0.0001) for patients with arginine depletion lasting less than 7 weeks. It is believed that treating patients with ADI-PEG 20 depletes circulating arginine, thus starving cancer cells of arginine, which is an essential amino acid for these cancers. These results in the starved cancer cells being unable to survive and grow while leaving the body's normal cells unharmed. The statistically significant findings from the analysis of the study data appear to support this hypothesis. Additionally, sorafenib naïve patients appear to have benefited more than those who failed prior sorafenib treatment, suggesting that ADI-PEG 20 may be more efficacious in the first-line setting. The study also showed ADI-PEG 20 was well tolerated, with the most common side effects being fatigue and decrease of appetite. The full study results were presented at a plenary session by the lead investigator, Dr. Ghassan K. Abou-Alfa from the Memorial Sloan Kettering Cancer Center, at the American Society of Clinical Oncology's 2016 annual meeting in Chicago. ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient's normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI-PEG 20.
Polaris Pharmaceuticals, Inc. Presents at ChinaBio Leadership Retreat 2015, Oct-22-2015
Sep 22 15
Polaris Pharmaceuticals, Inc. Presents at ChinaBio Leadership Retreat 2015, Oct-22-2015 . Venue: Changshu, China.
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus FOLFOX
Feb 3 15
Polaris Group announced that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) for the treatment of advanced gastrointestinal malignancies. Â In addition to a global Phase 3 study in hepatocellular carcinoma (HCC) featuring ADI-PEG 20 as a monotherapy, Polaris Group is currently conducting clinical trials on ADI-PEG 20 in combination with cisplatin in melanoma and ovarian cancer, in combination with sorafenib in HCC, in combination with doxorubicin in HER2 negative breast cancer, in combination with nab-paclitaxel and gemcitabine in pancreatic cancer and in combination with cisplatin and pemetrexed in malignant pleural mesothelioma and non-small cell lung carcinoma.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries